DDS

Belo Horizonte, Brazil
Belo Horizonte, Brazil
SEARCH FILTERS
Time filter
Source Type

Renowned style director, photographer to guide photo shoot for dental lifestyle magazine's 7th annual compilation May 11, 12 PITTSTON, PA--(Marketwired - May 09, 2017) - Incisal Edge, the leading lifestyle magazine for dental professionals nationwide, will celebrate America's finest young practitioners for their achievements in dentistry at a two-day event in Manhattan's Lower East Side later this week. Fortunately, these professionals are used to a feverish pace. The itinerary for 2017 honorees, Incisal Edge's "40 Under 40," includes an exclusive high fashion photo shoot at Zen House in New York City and a whirlwind celebration of all that they have achieved thus far in their professional careers. On May 11 and 12, 40 of the top young dentists in the nation will put their chairside techniques on hold and prepare to be preened on location by magazine staff and celebrated style director Joseph DeAcetis and photographer Matt Furman. The photography portfolio they create will serve as the centerpiece of the magazine's Fall issue. Hu-Friedy and KaVo Kerr Group will sponsor the event, featuring graffiti artist and author Erik Wahl. "The Incisal Edge '40 Under 40' are through the sheer force of their commitment and expertise, helping our profession ascend to even greater heights in the years ahead," says Chuck Cohen, founder of Incisal Edge dental lifestyle magazine. "We are very proud to honor the brightest rising dental stars in the U.S." Among this year's Incisal Edge 40 Under 40 recipients are 18 women and 24 men from 24 states: Dr. Taite R. Anderson, Granger Oral Surgery, Granger, Indiana, Dr. Hesham Baky, Triangle Family Dentistry, Morrisville, North Carolina, Dr. Katie Ball, Bling Dental, Portland, Oregon, Dr. Daniel Boehne, Dana Point Endodontics, Dana Point, California, Dr. Josh Bresler, Doc Bresler's Cavity Busters, Philadelphia, Pennsylvania, Dr. Mark Broomhead, Compton and Broomhead Dental Center, Munster, Indiana, Dr. Pearl Ambrosio Caligiuri, Northeast Valley Health Corporation, Canyon County, California, Dr. Marcus Capalbo, Scituate Family Dental, Scituate, Rhode Island and Thames River Dental, New London, Connecticut, Dr. Theodore Kerry Chamberlain, Chamberlain General and Sedation Dentistry, Clearwater, Florida, Dr. Abigael Seung Yon Cho, Marina Park Dental, San Francisco, California, Dr. Robert Christy, Kirkwood Dental Associates, Wilmington, Delaware, Dr. Jeremy Crow, Crow Dental Associates, Weirton, West Virginia, Dr. Nuri Eraydin, Maple Glen Dental Associates, Maple Glen, Pennsylvania, Dr. Benjamin Farrow, Monroe Street Family Dental, Madison, Wisconsin, Dr. Vivian Graham, Modern Micro Endodontics, Jersey City, New Jersey, Dr. Alisha Gray, Smile Works Family Dentistry, Plain City, Ohio, Dr. David Lee Hill Jr., Chapel Hill Implant and Oral Surgery Center, Chapel Hill, North Carolina, Dr. Jesse Jackson, Jackson Family Dental, Liberty Missouri, Dr. Andy Janiga, Mosier Troop Dental Clinic, Fort Lee, Virginia, Dr. Crystal Johnson, Johnson Family Dentistry, Powder Springs, Georgia, Dr. Joseph R. Karam, Karam Orthodontics, Scranton, Pennsylvania, Dr. Sarah Khan, Seattle Sound Dental, Seattle, Washington, Dr. Joseph G. Landry II, Landry Family Dentistry, Seville, Ohio, Dr. Courtney Lavigne, Courtney Lavigne Dentistry, Wayland, Massachusetts, Dr. Camille Little, Little Family Dentistry, Bayonne, New Jersey, Dr. Holly McKnight, AZPerio, Scottsdale, Arizona, Dr. John M. McMahon, McMahon Family Dental, Jenison, Michigan, Dr. Sharon Maloney, Summit Periodontics and Dental Implants LLC, Summit, New Jersey, Dr. Rosalie Nguyen, Edgewater Pediatric Dentistry, Edgewater, New Jersey, Dr. Sarah Palmer, Sarah Palmer DDS, Grandville, Michigan, Dr. Roshan Parikh, Chicagoland Smile Group, Chicago, Illinois, Dr. Natalie Pennington, Designer Family Dental, Delray Beach, Florida, Dr. Rashad Riman, R Dental Group, Beverly Hills, California, Dr. Leedia Riman, R Dental Group, Beverly Hills, California, Dr. Rawad Riman, R Dental Group, Beverly Hills, California, Dr. Kunal Saggar, CloudLake Dentistry + Dermatology, Jericho, New York, Dr. Andrew Sami, Gold Coast Smiles, PLLC, Glen Cove, New York, Dr. Sam Shin, DentiStar, Glenview, Illinois, Dr. Wah-Yung Tsang, Texas Mobile Dentists, San Antonio, Texas, Dr. Katherine Vo, Katherine Vo, D.D.S., San Francisco, California, Dr. Whitney D. Weiner, Board Certified Periodontist in Birmingham, Michigan, Dr. Paul Zhivago, Greene Street Dental, Manhattan, New York. Published by Benco Dental, Incisal Edge celebrates dentists' achievements both inside the operatory and during their hard-earned downtime -- and nothing better exemplifies this than the magazine's annual 40 Under 40 edition, a series of informative profiles of the finest young practitioners in our industry. Whether they're renowned for their medical innovations, their volunteer work and philanthropy or simply their commitment to outstanding patient care, these 40 honorees- nominated by industry experts from around the country and vetted by an independent panel -- represent the best of dentistry today, and the promise of even better dentistry tomorrow. To learn more about Incisal Edge, visit: http://www.incisaledgemagazine.com/ About Incisal Edge Knowledge. Success. Life. Those three words, printed on the cover of every issue, guide editorial content for the national's only dental lifestyle magazine -- Incisal Edge. Published by Benco Dental, Incisal Edge celebrates dentists' achievements both inside the operatory and during their hard-earned downtime. Known for its "40 Under 40" feature that highlights the country's brightest rising stars, the magazine's content ranges from "The 32 Most Influential People in Dentistry" and news about the latest techniques, tools, and dental practice designs, to the best in travel, automobiles, and timepieces. Incisal Edge reaches more than 40,000 Benco customers and their staffs; this number continues to grow due to media partnerships and a subscription option. About Benco Dental Benco Dental, headquartered in Northeastern Pennsylvania, is the largest privately-owned dental distributor in the United States, offering a full array of supplies, equipment and services to dentists across the nation. Founded in 1930 by Benjamin Cohen, the company has remained family-owned and focused on its unique mission to "deliver success, smile after smile." Within the past 86 years, the company has grown from a single downtown location to a national network of more than 65 regional locations, five distribution centers, and three design showrooms. Those design showrooms, one at the company's Pa. headquarters, one in Southern California, and one in Texas, feature North America's largest selection of dental equipment and technology, as well as a hands-on dental design experience, to assist dentists in the planning and construction of a new office. In addition to offering the market's broadest choice of equipment and supplies, Benco features a suite of innovative material management tools like Painless®, its industry-leading on-line inventory management system, and BluChips®, dentistry's original and most rewarding frequent buyer club. Through alliances with selected Success Services, Benco also offers practice coaching, continuing education, equipment financing, and wealth management services. Benco, which has been named one of the Best Workplaces in Health Care for the second consecutive year, and Pennsylvania's Best Places to Work® for 12 of the past 14 years, is proud to feature a highly skilled team of more than 400 professionally trained sales representatives and over 300 factory-trained service technicians. For more information, visit benco.com or call 1.800.GO.BENCO.


Gehan Jallaq, DDS, General and Cosmetic Dentist currently working within Westview Dental Center, has been named a 2017 Top Doctor in Columbus, Ohio. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Gehan Jallaq has been in practice for over a decade, and in that time has become renowned as one of the top dentists in Columbus. Her career in dentistry began in 2005, when she obtained her Doctor of Dental Surgery Degree from the University of Illinois at Chicago. Dr. Jallaq has completed numerous advanced training courses while working as a dentist, and additionally holds a Certificate of Completion of Advanced Clinical Studies. Dr. Jallaq and her dedicated team provide a wide range of general, cosmetic, and restorative dental services to patients across the age spectrum. Expert procedures carried out by her include the fitting of bridges and crowns, root canal treatment, treatments for periodontal disease, dental implants and full and partial dentures. Cosmetic dental services provided by Dr. Jallaq include teeth whitening and the use of porcelain crowns and veneers. She is also a certified provider of Fastbraces. Dr. Jallaq is committed to staying up to date with the latest advances in dental technology, and she does this through her active memberships with professional organizations such as the American Dental Association, the Chicago Dental Society, and the Columbus Dental Society. Her expertise as a general and cosmetic dentist makes Dr. Gehan Jallaq a very worthy winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


News Article | May 11, 2017
Site: www.businesswire.com

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced operating results for the 13 weeks ended April 29, 2017. This release contains certain forward-looking statements. Please refer to the Company’s cautionary statements regarding forward-looking information included below under “Forward-Looking Information.” Dillard’s reported net income for the 13 weeks ended April 29, 2017 of $66.3 million, or $2.12 per share, compared to net income of $77.4 million, or $2.17 per share, for the prior year first quarter. Net sales for the 13 weeks ended April 29, 2017 were $1.418 billion and $1.503 billion for the 13 weeks ended April 30, 2016. Net sales includes the operations of the Company’s construction business, CDI Contractors, LLC (“CDI”). Total merchandise sales (which excludes CDI) for the 13-week period ended April 29, 2017 were $1.386 billion and $1.449 billion for the 13-week period ended April 30, 2016. Total merchandise sales decreased 4% for the 13-week period ended April 29, 2017. Sales in comparable stores for the period also decreased 4%. Sales of ladies’ apparel notably outperformed other merchandise categories during the first quarter followed by the juniors’ and children’s apparel category. Weaker performances were noted in cosmetics, home and furniture, and ladies’ accessories and lingerie. Sales were strongest in the Western region followed by the Eastern and Central regions, respectively. Dillard’s Chief Executive Officer, William T. Dillard, II, stated, “While our sales decline weighed heavily on our operating results, we remained active in returning cash to shareholders through $93 million of share repurchase and dividends. We still ended the quarter with $302 million of cash largely due to better cash management.” Gross margin from retail operations (which excludes CDI) improved 65 basis points of sales for the 13 weeks ended April 29, 2017 compared to the prior year first quarter. Consolidated gross margin for the 13 weeks ended April 29, 2017 improved 108 basis points of sales compared to the prior year first quarter. Inventory increased 4% at April 29, 2017 compared to April 30, 2016. Selling, general and administrative expenses (“operating expenses”) were $398.5 million (28.1% of sales) and $398.4 million (26.5% of sales) during the 13 weeks ended April 29, 2017 and April 30, 2016, respectively. During the 13 weeks ended April 29, 2017, the Company purchased $91.1 million (approximately 1.7 million shares) of Class A Common Stock under its $500 million share repurchase program. At April 29, 2017 the remaining authorization under the February 2016 plan was $162.7 million. Total shares outstanding (Class A and Class B Common Stock) at April 29, 2017 and April 30, 2016 were 30.5 million and 35.2 million, respectively. During the quarter, Dillard’s opened its new replacement store at The Mall at Greenhills in Nashville, Tennessee (180,000 square feet). The Company purchased a former Macy’s location at Layton Hills Mall in Layton, Utah (160,000 square feet) and a store at Temple Mall in Temple, Texas that will replace a leased location at that center. Dillard’s expects to open both stores in the fall of 2017. Dillard’s operates 268 Dillard’s locations and 25 clearance centers spanning 29 states and an Internet store at www.dillards.com. Total store square footage is 49.2 million. The Company is providing the following estimates for certain financial statement items for the fiscal year ending February 3, 2018 based upon current conditions. Actual results may differ significantly from these estimates as conditions and factors change - See “Forward-Looking Information.” The foregoing contains certain “forward-looking statements” within the definition of federal securities laws. The following are or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995: statements including (a) words such as “may,” “will,” “could,” “believe,” “expect,” “future,” “potential,” “anticipate,” “intend,” “plan,” “estimate,” “continue,” or the negative or other variations thereof, and (b) statements regarding matters that are not historical facts. The Company cautions that forward-looking statements contained in this report are based on estimates, projections, beliefs and assumptions of management and information available to management at the time of such statements and are not guarantees of future performance. The Company disclaims any obligation to update or revise any forward-looking statements based on the occurrence of future events, the receipt of new information, or otherwise. Forward-looking statements of the Company involve risks and uncertainties and are subject to change based on various important factors. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements made by the Company and its management as a result of a number of risks, uncertainties and assumptions. Representative examples of those factors include (without limitation) general retail industry conditions and macro-economic conditions; economic and weather conditions for regions in which the Company’s stores are located and the effect of these factors on the buying patterns of the Company’s customers, including the effect of changes in prices and availability of oil and natural gas; the availability of consumer credit; the impact of competitive pressures in the department store industry and other retail channels including specialty, off-price, discount and Internet retailers; changes in consumer spending patterns, debt levels and their ability to meet credit obligations; changes in tax legislation; changes in legislation, affecting such matters as the cost of employee benefits or credit card income; adequate and stable availability and pricing of materials, production facilities and labor from which the Company sources its merchandise; changes in operating expenses, including employee wages, commission structures and related benefits; system failures or data security breaches; possible future acquisitions of store properties from other department store operators; the continued availability of financing in amounts and at the terms necessary to support the Company’s future business; fluctuations in LIBOR and other base borrowing rates; potential disruption from terrorist activity and the effect on ongoing consumer confidence; epidemic, pandemic or other public health issues; potential disruption of international trade and supply chain efficiencies; world conflict and the possible impact on consumer spending patterns and other economic and demographic changes of similar or dissimilar nature. The Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended January 28, 2017, contain other information on factors that may affect financial results or cause actual results to differ materially from forward-looking statements.


News Article | May 12, 2017
Site: marketersmedia.com

The popular family & cosmetic dental care practice, Alpine Meadows Family Dental with appointments at (801) 492-9207, announced an expansion of its cosmetic, restorative, general and preventive dentistry services available for patients in Lehi Utah, looking for lasting oral health and a beautiful, white, confident smile. The renowned Alpine Meadows Family Dental practice has announced an expansion of the highly popular, trusted and sought after cosmetic and general dentistry services it provides patients of all ages across Lehi and Utah County in their new location. More information is available https://www.alpinemeadowsfamilydental.com/ Alpine Meadows Family Dental is an acclaimed dental care practice based in Lehi Utah, drawing on the unique education and experience of Daniel Baird DDS to provide patients with the quality cosmetic, restorative, general and preventive dentistry services they need for lasting oral health and a flawless smile they can be proud of. Details found at https://www.alpinemeadowsfamilydental.com/cosmetic The dental care practice has now announced an expansion of its comprehensive and industry leading line of dentistry services which include simple, gentle and thorough cleanings or exams to detect and deter any oral health issues and all the premier tooth whitening, bridges, fillings, porcelain veneers, implants or dentures required to attain and maintain the most beautiful, white and healthy smile. Its range of cosmetic and family dentistry services, also offering essential root canal and periodontal disease treatments or custom night guards and sedation dentistry for those that have a fear of the dentist or anxiety, are all provided in a welcoming, comfortable and professional setting out a conveniently located at 1020 S 1100 W, Ste A Lehi, UT 84043. More details at https://www.alpinemeadowsfamilydental.com/services/restorative Appointments and consultations with Alpine Meadows Family Dental and more information on the leading range of cosmetic, restorative, general and preventive dentistry services it provides patients of all ages in Lehi Utah and all Utah County, can be requested at (801) 492-9207 or through the website link provided above along with multiple patients testimonials or details on its current Smile Out Loud Program by Referring a friend, and receive a $25 gift card For more information, please visit https://www.alpinemeadowsfamilydental.com


News Article | May 9, 2017
Site: www.prweb.com

ADLINK Technology, a global provider of leading edge computing solutions that drive data-to-decision applications across industries, together with LCR Embedded Systems, will showcase an integrated demonstration with SWaP-optimized, rugged unmanned systems preprocessing, communicating and distributing real-time data to decision makers. The demonstration takes place in Booth 306 at AUVSI XPONENTIAL 2017, May 9 – May 11, at Kay Bailey Hutchison Convention Center in Dallas, TX. The demonstration will consist of two connected SWaP/C-friendly rugged systems suitable for deployment on unmanned vehicles, one from ADLINK and one from LCR Embedded Systems. A drone-mountable camera will be connected to the ADLINK HPERC™ system utilizing PrismTech’s Vortex DDS software, enabling the camera to capture, track, and transmit several targets simultaneously. This information will then be transmitted in real time to LCR Embedded Systems’ recently announced Featherweight VPX System, powered by Intel® Xeon® D processor, illustrating communication to a receiving system where it can be further processed and distributed. “One of the most important things to keep in mind about any unmanned vehicle system is that the system doesn’t stop at the vehicle,” said LCR Embedded Systems President David Pearson. “The vehicle is only the most peripheral part of a much larger distributed system that might be composed of other air, land, and marine vehicles, portable and fixed ground stations, and more. LCR Embedded Systems is thrilled to exhibit at AUVSI XPONENTIAL 2017 with valued partner ADLINK Technologies to show how, together, we can offer complete solutions that slot in at any point within unmanned vehicle systems, no matter how extensive they may be.” “Unmanned systems provide a quantum leap in the way battlefield information is gathered. As these systems accelerate and evolve, sensor and data processing requirements challenge the performance envelope of small form factor, ruggedized, high performance computing solutions,” said Elizabeth Campbell, General Manager at ADLINK Americas. “We are excited to showcase LCR Embedded’s chassis designs and system platforms based on ADLINK's Extreme Rugged™ small form factor boards, computer-on-modules, and slot card architectures such as AdvancedTCA®, CompactPCI®, and VPX boards.” For more information on AUVSI XPONENTIAL 2017 or to register for an expo pass, please visit http://www.xponential.org/xponential2017/public/Content.aspx?ID=2207 About LCR Embedded Systems LCR Embedded Systems designs, develops, and manufactures rugged and lab-grade chassis, backplanes, and fully integrated systems for the aerospace and defense, commercial, rail, and industrial markets with a focus on standards-based form factors such as VPX/VME, AdvancedTCA, COM Express, and CompactPCI. LCR Embedded Systems is an AS 9100 C and ISO9001:2008 certified company, with approved J-STD-001 Class 3, CCAP, FOD, and ESD programs in place. About ADLINK ADLINK Technology is leading edge computing with solutions that drive data-to-decision applications across industries. Our products include motherboards, blades, chassis, modules, gateways, systems and end-to-end solutions based on industry standard form factors. Many products are Extreme Rugged™, supporting extended operating temperature ranges, and MIL-STD levels of shock and vibration. ADLINK is active in several standards organizations and interoperability initiatives. For more information, please visit http://www.adlinktech.com. # # # All trademarks are the property of their respective owners in the U.S. and other countries.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


The International Association of HealthCare Professionals is pleased to welcome Steven S. Broughton, DDS, General, Family, and Cosmetic Dentist to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Steven S. Broughton is a highly trained and qualified dentist with an extensive expertise in all facets of his work. He has been in practice for two decades and is currently serving patients as the President within Light Dental Studios in Puyallup, Washington. Dr. Broughton gained his Doctor of Dental Surgery Degree in 1997 from the University of Washington School of Dentistry in Seattle. Since graduating, he has completed advanced training in many areas while working as a dentist, and is a certified Invisalign provider. He is also certified in both Oral Surgeries and Periodontal Surgeries. To stay current in his field, Dr. Broughton maintains a professional membership with the American Dental Association, the Washington State Dental Association, the Pierce County Dental Society, and the American College of Dentists. For his wealth of experience and knowledge, Dr. Broughton is the recipient of numerous prestigious awards and recognitions. He attributes his success to working hard, as well as genuinely caring for his patients and coworkers. In his free time, Dr. Broughton enjoys spending time with his wife and two daughters. Learn more about Dr. Broughton here: http://www.lightdentalstudios.com/ and by reading his upcoming publication in the Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


News Article | May 8, 2017
Site: www.businesswire.com

VANCOUVER, British Columbia--(BUSINESS WIRE)--Absolute® (TSX: ABT), the self-healing endpoint security company, today announced financial results for the three and nine months ended March 31, 2017. All dollar figures are unaudited and stated in U.S. dollars, unless otherwise indicated. “ Our Q3 results were underscored by strong expansion and upsell activity within customer accounts, demonstrating the inherent opportunities among our customer base and the response to our accelerated product innovation,” said Geoff Haydon, Chief Executive Officer, Absolute. “ Over the first nine months of fiscal 2017, we demonstrated our ability to execute on multiple growth vectors with both new customer acquisition and existing customer expansion driving year-to-date revenue performance.” i. As a result of the divestiture of the Absolute Manage and Absolute Service business unit on October 5, 2015, the Data and Device Security operating segment solely comprises Absolute’s ongoing operations. This measure is specifically related to our DDS operating segment. ii. Please refer to “Non-IFRS Measures and Definitions”. iii. Adjusted EBITDA in the year to date period of F2016 included a $1.0 million contribution from the Absolute Manage and Absolute Service business unit. This business unit was disposed in Q2-F2016. The Company is narrowing its revenue guidance to the lower end of the previous guidance range reflecting lower than expected professional services and Consumer sales. F2017 total revenue is expected to be between $91.4 million and $92.4 million, representing 6% to 8% annual DDS segment revenue growth. The Company is raising its Adjusted EBITDA guidance to 8% to 9% of revenue. The Company expects cash from operating activities, prior to payments for income taxes and reorganization charges, as a percentage of revenue, to be 7% to 9%. Capital expenditures are expected to be between $3.8 million and $4.2 million. Quarterly Dividend On April 19, 2017, Absolute declared a quarterly dividend of CAD$0.08 per share on the Company’s common shares. The dividend is payable in cash on May 29, 2017 to shareholders of record at the close of business on May 9, 2017. Quarterly Filings Management’s discussion and analysis (“MD&A”) and consolidated financial statements and the notes thereto for the fiscal quarter ended March 31, 2017 can be obtained today from Absolute’s corporate website at www.absolute.com. The documents will also be available at www.sedar.com. Notice of Conference Call Absolute will hold a conference call to discuss the Company’s Q3-F2017 results on Monday, May 8, 2017 at 5:00 p.m. ET. All interested parties can join the call by dialing 647-427-7450, or 1-888-231-8191. Please dial-in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until Monday, May 15, 2017 at midnight ET. To access the archived conference call, please dial 416-849-0833 or 1-855-859-2056 and enter the reservation code 5155053. A live audio webcast of the conference call will be available at www.absolute.com and http://bit.ly/2oPgdfG. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available on the Company’s website for 90 days. Non-IFRS Measures and Definitions Throughout this press release, the Company refers to a number of measures which the Company believes are meaningful in the assessment of the Company’s performance. All these metrics are non-standard measures under International Financial Reporting Standards (“IFRS”), and are unlikely to be comparable to similarly titled measures reported by other companies. Readers are cautioned that the disclosure of these items is meant to add to, and not replace, the discussion of financial results or cash flows from operations as determined in accordance with IFRS. For a discussion of the purpose of these non-IFRS measures, please refer to the Company’s March 31, 2017 MD&A on SEDAR at www.SEDAR.com. These measures, as well as their method of calculation or reconciliation to IFRS measures, are as follows: 1) Commercial ACV Base, Net ACV Retention, and ACV from New Customers As the majority of the Company’s customer contracts are sold under multi-year term licenses, there is a significant lag between the timing of the Billing and the associated revenue recognition. As a result, the Company focuses on the aggregate annualized value of its subscriptions under contract, measured by Annual Contract Value (“ACV”), as an indicator of its future revenues. Commercial ACV Base measures the amount of recurring annual revenue Absolute will receive from its commercial customers under contract at a point in time, and therefore is an indicator of the Company’s future revenue streams. Net ACV Retention measures the percentage increase or decrease in the Commercial ACV Base at the end of a period for the customers that comprised the Commercial ACV Base at the beginning of the same period. This metric provides insight into the effectiveness of Absolute’s customer retention and expansion functions. ACV from New Customers measures the addition to the Commercial ACV base from sales to new commercial DDS customers during the quarter. We believe that increases in the amount of ACV from New Customers, and improvement in the Company’s Net ACV Retention, will grow our Commercial ACV Base and, in turn, our future revenues. 2) Adjusted EBITDA Management believes that analyzing operating results exclusive of significant non-cash items or items not controllable in the period provides a useful measure of the Company’s performance. The term Adjusted EBITDA refers to earnings before deducting interest and investment gains (losses), income taxes, amortization of acquired intangible assets and property and equipment, foreign exchange gain or loss, share-based compensation, and restructuring and reorganization charges and post-retirement benefits. The items excluded in the determination of Adjusted EBITDA are share-based compensation, amortization of acquired intangibles, amortization of property and equipment, and restructuring and reorganization charges and certain post-retirement benefits. 3) Adjusted Operating Expenses A number of significant non-cash or non-recurring expenses are reported in the Company’s Cost of Revenue and Operating Expenses. Management believes that analyzing these expenses exclusive of these non-cash or non-recurring items provides a useful measure of the cash invested in the operations of its business. The items excluded in the determination of Adjusted Operating Expenses are share-based compensation, amortization of acquired intangible assets, amortization of property and equipment, and restructuring and reorganization charges and certain post-retirement benefits. For a description of the reasons these items are adjusted, please refer to the “Non-IFRS Measures” section of the March 31, 2017 MD&A. 4) Billings See the “Non-IFRS Measures” section of the March 31, 2017 MD&A for a detailed discussion of why the Company believes Cash from Operating Activities is a meaningful performance metric, and the material impact that Billings has on this measure. Billings are included in deferred revenue (see Note 7 of the Notes to the Condensed Consolidated Financial Statements), and result from invoiced sales of the Company’s products and services. About Absolute Absolute (TSX: ABT) delivers the only self-healing endpoint security solution to provide uncompromised visibility and near real-time remediation of breaches at the source. Absolute’s cloud-based platform puts IT and security professionals in absolute control of devices, data and applications — whether on or off the corporate network — to enhance IT asset management, protect sensitive data, reduce insider threats and ensure compliance. Absolute’s patented Persistence technology is embedded in the firmware of more than 1 billion PCs and mobile devices from global manufacturers including Acer, ASUS, Dell, Fujitsu, HP, Lenovo, Microsoft, Panasonic, Samsung and Toshiba. Absolute is headquartered in Vancouver, Canada, and has offices around the world. For more information, visit www.absolute.com. This press release contains forward-looking statements and financial outlook that involve risks and uncertainties. These forward-looking statements and financial outlook relate to, among other things, the expected performance, functionality and availability of the Company’s services and products, and other expectations, intentions and plans contained in this press release that are not historical facts. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect the Company’s current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and general market conditions. In light of the many risks and uncertainties readers of the press release should understand that Absolute cannot assure them that the forward-looking statements and financial outlook contained in this press release will be realized. Furthermore, the forward-looking statements and financial outlook contained in this press release are made as at the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements and financial outlook, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. ©2017 Absolute Software Corporation. All rights reserved. Absolute and Persistence are registered trademarks of Absolute Software Corporation. For patent information, visit www.absolute.com/patents. The Toronto Stock Exchange has neither approved nor disapproved of the information contained in this news release. ABSOLUTE SOFTWARE CORPORATION Condensed Consolidated Statements of Financial Position (Expressed in United States dollars) (Unaudited) ABSOLUTE SOFTWARE CORPORATION Condensed Consolidated Statements of Operations and Comprehensive Income Three and nine months ended March 31, 2017 and 2016 (Expressed in United States dollars) (Unaudited) ABSOLUTE SOFTWARE CORPORATION Condensed Consolidated Statement of Changes in Shareholders’ Deficiency (Expressed in United States dollars) (Unaudited) ABSOLUTE SOFTWARE CORPORATION Condensed Consolidated Statements of Cash Flows Three and nine months ended March 31, 2017 and 2016 (Expressed in United States dollars) (Unaudited)

Loading DDS collaborators
Loading DDS collaborators